RESUMEN
A novel, highly sensitive and eco-friendly micellar-mediated spectrofluorimetric method was developed and validated for the determination of the novel antiparkinsonian drug safinamide mesylate in the presence of its related precursor impurity, 4-hydroxybenzaldehyde. The proposed approach relies on increasing the inherent fluorescence emission at 296 nm of safinamide, by forming hydrogen bonds between the mentioned drug and sodium dodecyl sulfate in the micellar system using 0.1 N HCl as a solvent, following excitation at 226 nm. A thorough investigation was conducted into the experimental factors affecting spectrofluorimetric behavior of the studied drug. A linearity plot of safinamide over the concentration range of 10.0-1000.0 ng/mL against the relative fluorescence intensities was established. The proposed method demonstrated excellent sensitivity down to the nano-gram level with detection and quantitation limits of 1.91 and 5.79 ng/mL, respectively. The studied drug was effectively determined in Parkimedine® Tablets. Furthermore, the proposed method allows for ultrasensitive quantification of safinamide in spiked human plasma, with satisfactory percentage recovery (98.97-102.28%). Additionally, the greenness assessment using the advanced green certificate classification approach, the complementary green analytical procedure index (Complex-GAPI), and the analytical GREEness metric approach (AGREE), along with the practicality check using the Blue Applicability Grade Index in addition to the all-inclusive overall whiteness evaluation using the RGB-12 model were carried out. The outcomes demonstrated the effectiveness and whiteness of the proposed technique. Clearly, the suggested approach has the advantages of being simple, requiring no pretreatment steps, and relying solely on direct measuring procedures.
Asunto(s)
Alanina , Antiparkinsonianos , Bencilaminas , Micelas , Espectrometría de Fluorescencia , Humanos , Espectrometría de Fluorescencia/métodos , Alanina/análogos & derivados , Alanina/sangre , Antiparkinsonianos/sangre , Antiparkinsonianos/análisis , Antiparkinsonianos/uso terapéutico , Bencilaminas/sangre , Bencilaminas/análisis , Bencilaminas/química , Comprimidos , Límite de Detección , Reproducibilidad de los ResultadosRESUMEN
Background: Levodopa is the gold standard of treatment in Parkinson's disease (PD). Its clinical effect changes as the disease progresses. Wearing off is a frequent first manifestation of motor fluctuations. Some patients with advanced PD report faster wearing off after physical exercise. Objective: The aim was to assess if pharmacokinetics of levodopa is influenced by physical exercise in patients with different disease advancement. Methods: 22 patients with PD (12 untreated with levodopa and 10 with motor fluctuations) and 7 healthy controls (HC) were included. Plasma samples were collected at 9 fixed timepoints following administration of levodopa/benserazide 200/50âmg for two days: rest day and standardized physical exercise day. Clinical assessment with Unified Parkinson Disease Rating Scale part III (UPDRS III) was performed in fixed timepoints. Liquid chromatography-tandem mass spectrometry was used to measure levodopa concentrations. Results: No differences between the HC, levodopa naïve and advanced PD groups were observed regarding selected pharmacokinetic parameters. In advanced PD and HC no differences in pharmacokinetic parameters of levodopa with and without effort were observed. In levodopa naïve PD group higher mean residence time after rest than after exercise (168.9±48.3âmin vs. 145.5±50.8âmin; pâ=â0.026) was observed. In advanced PD group higher UPDRS III score (14.45±5.5 versus 20.9±6.1 points, pâ=â0.04) was observed after exercise. Conclusions: The deterioration of motor status of advanced PD patients after physical effort is not reflected by changes in pharmacokinetics but rather mediated by central mechanisms.
Asunto(s)
Antiparkinsonianos , Ejercicio Físico , Levodopa , Enfermedad de Parkinson , Humanos , Levodopa/administración & dosificación , Levodopa/farmacocinética , Enfermedad de Parkinson/tratamiento farmacológico , Enfermedad de Parkinson/terapia , Enfermedad de Parkinson/sangre , Masculino , Femenino , Anciano , Persona de Mediana Edad , Antiparkinsonianos/administración & dosificación , Antiparkinsonianos/farmacocinética , Antiparkinsonianos/sangre , Ejercicio Físico/fisiología , Benserazida/administración & dosificación , Benserazida/farmacología , Combinación de Medicamentos , Progresión de la Enfermedad , Índice de Severidad de la EnfermedadRESUMEN
The monitoring and precise determination of pesticides and pharmaceutical drugs and their residues have become increasingly important in the field of food safety and water contamination issues. Herein, a fluorescent aluminium MOF-based sensor (1) was developed for the selective recognition of neonicotinoid insecticide dinotefuran and anti-Parkinson's drug entacapone. Guest-free MOF 1' exhibited ultra-fast response (<5â s) and ultra-low detection limits of 2.3 and 7.6â nM for dinotefuran and entacapone, which are lower than the previously reported MOF-based sensors. In the presence of other competitive analytes, great selectivity was achieved towards both analytes. The probe was recyclable up to five cycles. The sensing ability was explored towards entacapone in human serum, urine and dinotefuran in real soil, rice, honey samples, different fruits, vegetables, real water specimens and a wide range of pH media. A low-cost, handy MOF-based polymer thin-film composite (1'@PVDF-PVP) was developed for the on-site detection of dinotefuran and entacapone. Mechanistic studies involving analytical techniques and theoretical calculations suggested that FRET and PET are the probable reasons for entacapone sensing whereas IFE is responsible for dinotefuran detection. The entire work presents a low cost, multi-use photoluminescent sensor of entacapone and dinotefuran to address the environmental pollution.
Asunto(s)
Guanidinas , Insecticidas , Estructuras Metalorgánicas , Neonicotinoides , Nitrilos , Neonicotinoides/análisis , Neonicotinoides/orina , Estructuras Metalorgánicas/química , Humanos , Insecticidas/análisis , Insecticidas/sangre , Nitrilos/química , Guanidinas/análisis , Guanidinas/química , Guanidinas/sangre , Nitrofuranos/análisis , Antiparkinsonianos/análisis , Antiparkinsonianos/sangre , Colorantes Fluorescentes/química , Estructura Molecular , Límite de Detección , NitrocompuestosRESUMEN
While levodopa (L-Dopa) is the primary treatment for alleviating Parkinson's disease (PD), its efficacy is hindered by challenges such as a short half-life and inconsistent plasma levels. As PD progresses, the rising need for increased and more frequent L-Dopa doses coupled with symptom fluctuations and dyskinesias underscores the urgency for improved comprehension of the interplay between L-Dopa levels and PD motor symptoms. Addressing this critical need, we present a decentralized testing method using a disposable biosensor strip and a universal slope (U-slope) calibration-free approach. This enables reliable, rapid, simple, and cost-effective decentralized L-Dopa measurements from capillary blood. A pilot study with PD persons demonstrates the ability to monitor real-time L-Dopa pharmacokinetics from fingerstick blood after oral L-Dopa-Carbidopa (C-Dopa) tablet administration. Correlating capillary blood L-Dopa levels with PD motor scores revealed a well-defined inverse correlation with temporal motor fluctuations. We compared the resulting dynamic capillary blood L-Dopa levels with plasma L-Dopa levels using the traditional but clinically impractical high-performance liquid chromatography technique. By providing timely feedback on a proper L-Dopa dosing regimen in a decentralized and rapid fashion, this new biosensing platform will facilitate tailored optimal L-Dopa dosing, towards improving symptom management and enhancing health-related quality of life.
Asunto(s)
Técnicas Biosensibles , Levodopa , Enfermedad de Parkinson , Levodopa/farmacocinética , Levodopa/uso terapéutico , Levodopa/sangre , Levodopa/química , Enfermedad de Parkinson/tratamiento farmacológico , Humanos , Antiparkinsonianos/uso terapéutico , Antiparkinsonianos/farmacocinética , Antiparkinsonianos/administración & dosificación , Antiparkinsonianos/sangre , Carbidopa/farmacocinética , Carbidopa/uso terapéutico , Carbidopa/administración & dosificación , Proyectos Piloto , MasculinoRESUMEN
INTRODUCTION: Some patients with Parkinson's disease (PD) undergoing levodopaâcarbidopa intestinal gel (LCIG) treatment experience motor fluctuations in the afternoon. The migrating motor complex, a specific periodic migrating contraction pattern occurring in the stomach and small intestine during the fasting state, can affect drug absorption. We aimed to compare the pharmacokinetic parameters between two conditions (with and without lunch) and assessed the influence of the fasting state on the levodopa pharmacokinetics in LCIG treatment. METHODS: We evaluated the levodopa pharmacokinetics from 12:00 p.m. to 6:00 p.m. in 10 LCIG-treated PD patients in the presence and absence of lunch. RESULTS: The maintenance dose of LCIG correlated strongly with the mean plasma concentration of levodopa in the absence (r = 0.94, coefficient of determination (R2) = 0.89, p < 0.001) or presence of lunch (r = 0.96, R2 = 0.93, p < 0.001). Comparison of the pharmacokinetic parameters revealed that the coefficient of variation was significantly greater in the condition without lunch than in the condition with lunch (p = 0.004): 16.73% (4.88%) without lunch and 9.22% (3.80%) with lunch. There were no significant differences in the mean plasma concentration of levodopa (p = 0.49) and area under the plasma concentrationâtime curve (p = 0.27) between the two conditions. CONCLUSIONS: Plasma concentrations of levodopa fluctuated more in patients undergoing LCIG treatment without than with lunch. Our results indicate that a small amount of food intake may be a better corrective approach for worsening of symptoms in the fasting state rather than additional levodopa.
Asunto(s)
Antiparkinsonianos/farmacocinética , Carbidopa/farmacocinética , Ayuno/sangre , Levodopa/sangre , Enfermedad de Parkinson/tratamiento farmacológico , Anciano , Antiparkinsonianos/sangre , Combinación de Medicamentos , Ingestión de Alimentos/efectos de los fármacos , Femenino , Geles , Humanos , Intestinos/efectos de los fármacos , Levodopa/farmacocinética , Almuerzo/efectos de los fármacos , Masculino , Actividad Motora/efectos de los fármacos , Enfermedad de Parkinson/sangreRESUMEN
PURPOSE: Levodopa (LD) is the most effective oral pharmacotherapy for the management of motor symptoms in Parkinson's disease. However, LD use is complicated by a progressive shortening of the duration of efficacy of a dose, resulting in episodes of inadequate responsiveness, or OFF periods. OFF periods may also occur unpredictably, partly due to the pharmacokinetic (PK) variability of oral LD, resulting from gastrointestinal dysfunction and from the effects of food on absorption. CVT-301 is a levodopa inhalation powder for the treatment of OFF period symptoms in patients on oral dopa-decarboxylase inhibitor/LD. PK and safety profiles of single dose CVT-301, administered with oral carbidopa (CD) and oral CD/LD, were examined in patients with Parkinson's disease in the fed state. METHODS: Eligible patients were aged 30-85 years, with a clinical diagnosis of Parkinson's disease and a body mass index of 18-32 kg/m2, and were receiving treatment with a stable regimen that included oral CD/LD (25/100 mg) (total LD, ≤800 mg/d). A high-fat/protein meal was eaten 4-5 h after the administration of the morning oral CD/LD dose. Blood samples for predose PK analysis were obtained after the meal, followed by a single inhaled dose of CVT-301 84 mg (+25 mg of oral CD) or oral CD/LD (25/100 mg) or vice versa in 2 dosing periods in a crossover design. Blood was sampled at 0, 5, 10, 15, 30, and 45 min and at 1, 1.5, 2, 3, and 4 h postdose. Tolerability assessments included treatment-emergent adverse events. FINDINGS: Twenty-three patients were enrolled (65.2% male; 87.0% white; mean age, 69.3 years; mean body mass index, 26.9 kg/m2; mean Parkinson's disease duration, 8.2 years; mean baseline LD dosage, 460.9 mg/d; 73.9% at Hoehn and Yahr stage <2.5). PK analyses were based on LD concentrations without baseline adjustment. Median Tmax values with CVT-301 and oral CD/LD were 15 and 120 min (P < 0.001). Cmax with CVT-301 was lower than with oral CD/LD (590.3 vs 844.3 ng/mL). C10min and C30min values with CVT-301 were approximately twice those with CD/LD (522.9 and 531.5 ng/mL vs 247.3 and 300.9 ng/mL, respectively). %CV for C5min to Cmax with CVT-301 was lower than that with oral CD/LD. The most common treatment-emergent adverse event was cough (CVT-301, 7 patients [30.4%]; oral CD/LD, 1 patient [4.5%]). IMPLICATIONS: PK properties showed that CVT-301 was more rapidly absorbed, with higher plasma LD concentrations in the first 45 min, and demonstrated lower interpatient variability, than was oral CD/LD in the fed condition. The study findings suggest that CVT-301 can be used without regard to food intake. ClinicalTrials.gov identifier: NCT03887884.
Asunto(s)
Antiparkinsonianos/farmacocinética , Carbidopa/administración & dosificación , Levodopa/farmacocinética , Enfermedad de Parkinson/tratamiento farmacológico , Administración por Inhalación , Administración Oral , Anciano , Anciano de 80 o más Años , Antiparkinsonianos/administración & dosificación , Antiparkinsonianos/efectos adversos , Antiparkinsonianos/sangre , Carbidopa/efectos adversos , Estudios Cruzados , Femenino , Interacciones Alimento-Droga , Humanos , Levodopa/administración & dosificación , Levodopa/efectos adversos , Levodopa/sangre , Masculino , Persona de Mediana EdadRESUMEN
Levodopa, commonly used anti-Parkinson drugs in the clinic, is the most significant prodrug of dopamine that plays important roles in the treatment of Parkinson's disease. Therefore, monitoring content of levodopa of anti-parkinson drugs in human serum is extremely necessary. Herein, a simple, fast and low-cost method for levodopa detection is proposed depending on the in situ formation of blue and green emission fluorescent copolymer (FCP). The proposed method is based on the conversion of fluorescence emission peak of FCP from blue (430 nm) to green emission (535 nm) in 2 h. In this sensing system, both blue and green emission exhibit a high selectivity and sensitivity for levodopa determination in the range from 0 to 50 µM with a detection limit of 0.2 µM and 0.36 µM, respectively. Among them green emission FCP shows excellent recovery even at human serum concentrations up to 30%. Additionally, the proposed method was successfully applied to assess the content of levodopa in three anti-Parkinson drugs (carbidopa and levodopa CR tablets, levodopa and benserazide hydrochloride tablets, and levodopa tablets). More importantly, the levodopa determination of three anti-Parkinson drugs in human serum also exhibit an excellent recovery. Therefore, our strategy provides a promising method for mechanism study and treatment of Parkinson's disease.
Asunto(s)
Antiparkinsonianos/sangre , Colorantes Fluorescentes/química , Levodopa/sangre , Polímeros/química , Humanos , Tamaño de la Partícula , Espectrometría de Fluorescencia , Propiedades de SuperficieRESUMEN
BACKGROUND AND OBJECTIVES: Levodopa concentration in patients with Parkinson's disease is frequently modelled with ordinary differential equations (ODEs). Here, we investigate a pharmacokinetic model of plasma levodopa concentration in patients with Parkinson's disease by introducing stochasticity to separate the intra-individual variability into measurement and system noise, and to account for auto-correlated errors. We also investigate whether the induced stochasticity provides a better fit than the ODE approach. METHODS: In this study, a system noise variable is added to the pharmacokinetic model for duodenal levodopa/carbidopa gel (LCIG) infusion described by three ODEs through a standard Wiener process, leading to a stochastic differential equations (SDE) model. The R package population stochastic modelling (PSM) was used for model fitting with data from previous studies for modelling plasma levodopa concentration and parameter estimation. First, the diffusion scale parameter (σw), measurement noise variance, and bioavailability are estimated with the SDE model. Second, σw is fixed to certain values from 0 to 1 and bioavailability is estimated. Cross-validation was performed to compare the average root mean square errors (RMSE) of predicted plasma levodopa concentration. RESULTS: Both the ODE and the SDE models estimated bioavailability to be approximately 75%. The SDE model converged at different values of σw that were significantly different from zero. The average RMSE for the ODE model was 0.313, and the lowest average RMSE for the SDE model was 0.297 when σw was fixed to 0.9, and these two values are significantly different. CONCLUSIONS: The SDE model provided a better fit for LCIG plasma levodopa concentration by approximately 5.5% in terms of mean percentage change of RMSE.
Asunto(s)
Antiparkinsonianos/administración & dosificación , Antiparkinsonianos/farmacocinética , Antiparkinsonianos/uso terapéutico , Levodopa/administración & dosificación , Levodopa/farmacocinética , Enfermedad de Parkinson/tratamiento farmacológico , Medicina de Precisión/métodos , Anciano , Antiparkinsonianos/sangre , Disponibilidad Biológica , Carbidopa , Combinación de Medicamentos , Femenino , Humanos , Levodopa/sangre , Levodopa/uso terapéutico , Masculino , Persona de Mediana Edad , Modelos Biológicos , Procesos EstocásticosRESUMEN
Peaks and troughs of levodopa in plasma contribute to pulsatile postsynaptic dopamine receptor stimulation in patients with Parkinson's disease. Measurement of levodopa plasma levels mostly only considers the total levodopa plasma concentration. Objectives were to determine bound, free, and total plasma levodopa and to investigate their correlations to each other. We employed reversed-phase high-performance liquid chromatography combined with electrochemical detection. Bound levodopa was computed as difference between total and free L-dopa values. Close correlations between free and total (R = 0.93, p < 0.0001), bound and total (R = 0.91, p < 0.0001) plasma levodopa appeared. A considerable variability of levodopa concentrations occurred. The ratio between bound and free levodopa did not differ in patients with a higher and lower oral daily levodopa dosing. Free, bound, and total levodopa plasma levels are closely related. Estimation of the total levodopa level only seems to be meaningful.
Asunto(s)
Antiparkinsonianos/sangre , Levodopa/sangre , Enfermedad de Parkinson/tratamiento farmacológico , Anciano , Antiparkinsonianos/administración & dosificación , Femenino , Humanos , Levodopa/administración & dosificación , Masculino , Persona de Mediana Edad , Enfermedad de Parkinson/sangreRESUMEN
Objective Assessing daily motor fluctuations is an important part of the disease management for patients with Parkinson's disease (PD). However, the frequent recording of subjective and/or objective assessments is not always feasible, and easier monitoring methods have been sought. Previous studies have reported that the spontaneous eye-blink rate (EBR) is correlated with the dopamine levels in the brain. Thus, the continuous monitoring of the EBR may be useful for predicting the motor status in patients with PD. Methods Electrooculograms (EOGs) were recorded for up to 7.5 hours from three PD patients using a wearable device that resembled ordinary glasses. An receiver operating characteristic (ROC) analysis was performed to compare the ability of the EBR estimates at each time-point (Blink Index) and the plasma levodopa levels to predict the motor status. Results The Blink Index was correlated with the plasma levodopa levels. When an indicator for the first hour of the observation period was included in the model, the Blink Index discerned wearing-off and dyskinesia as accurately as the plasma levodopa level. Conclusion Our study provides preliminary evidence regarding the utility of continuous EBR monitoring for the non-invasive evaluation of the motor status in patients with PD.
Asunto(s)
Parpadeo/fisiología , Destreza Motora/fisiología , Enfermedad de Parkinson/fisiopatología , Anciano , Antiparkinsonianos/sangre , Dopaminérgicos/sangre , Femenino , Humanos , Levodopa/sangre , Masculino , Persona de Mediana Edad , Enfermedad de Parkinson/tratamiento farmacológico , Valor Predictivo de las Pruebas , Curva ROCRESUMEN
A new levodopa-carbidopa intestinal gel (LCIG) system featuring a higher levodopa/carbidopa (LD/CD) concentration and viscosity, LCIG-HV, is being developed to reduce the intrajejunal volume of LD/CD that is administered as compared to the current commercial formulation, LCIG-LV. This study characterizes the LCIG-HV formulation and compares it to the LCIG-LV formulation via dissolution testing and a clinical pharmacokinetic bioequivalence study. In vitro release profiles of LD/CD were determined using a USP Dissolution Apparatus 2 with 500 mL of phosphate buffer (pH 4.5) operating at 25 RPM. A single dose, open-label study was conducted according to a two-period, randomized, crossover design in 28 healthy subjects. The point estimate (PE) of the levodopa Cmax geometric mean for the LCIG-HV formulation was 4% higher than that of the LCIG-LV formulation. PEs of levodopa AUCt and AUCinf geometric means were comparable for both formulations. PEs of carbidopa Cmax , AUCt and AUCinf geometric means for the LCIG-HV formulation were 3%-5% higher than those of the LCIG-LV formulation. For both formulations, the median Tmax for levodopa was 1.0 and 3.0 hours for carbidopa. The levodopa half-life harmonic mean was 1.6 hour for both formulations. The carbidopa half-life harmonic mean was 1.9 and 2.0 hour, respectively, for the LCIG-HV and LCIG-LV formulations. Cmax , AUCt and AUCinf of LD/CD carbidopa were comparable for both formulations. The current study demonstrates that the LCIG-LV and LCIG-HV formulations are clinically bioequivalent for LD/CD according to FDA guidance. However, the dissolution method was over discriminatory of formulation differences.
Asunto(s)
Antiparkinsonianos/química , Antiparkinsonianos/farmacocinética , Carbidopa/química , Carbidopa/farmacocinética , Levodopa/química , Levodopa/farmacocinética , Adulto , Antiparkinsonianos/efectos adversos , Antiparkinsonianos/sangre , Carbidopa/efectos adversos , Carbidopa/sangre , Estudios Cruzados , Combinación de Medicamentos , Liberación de Fármacos , Femenino , Geles , Humanos , Levodopa/efectos adversos , Levodopa/sangre , Masculino , Persona de Mediana Edad , Equivalencia TerapéuticaRESUMEN
BACKGROUND: Magnesium oxide (MgO) is often co-prescribed with L-dopa/carbidopa (LDCD) to improve constipation in Parkinson's disease patients. The mixing of L-dopa and MgO has been shown to degrade L-dopa; however, there is no interaction study on humans. We proposed mechanisms for the interaction between LDCD and MgO and conducted pharmacokinetic studies on rats and humans. To assess pharmacodynamic changes with the MgO treatment, we applied a model-based meta-analysis (MBMA). METHODS: The effects of MgO on the stabilities of L-dopa and carbidopa were evaluated in in vitro studies. We conducted pharmacokinetic interaction studies of MgO and LDCD on rats and healthy volunteers. A clinical study was conducted with an open-label, non-randomized, single-arm, and two-phase study. In MBMA, we constructed a population pharmacokinetic/pharmacodynamic model of L-dopa and predicted the effects of the MgO treatment on the pharmacodynamics of L-dopa. RESULTS: In vitro results suggested that carbidopa was unstable under alkaline pH conditions. Reductions in plasma LDCD concentrations were observed after oral-MgO/oral-LDCD, but not in oral-MgO/i.v.-LDCD treatments in rats, suggesting that the gastrointestinal tract is an interaction site. A healthy volunteer study showed that MgO was also associated with significant decreases of 35.3 and 80.9% in the AUC0-12 of L-dopa and carbidopa, respectively. A model-based simulation suggested that the MgO treatment was undesirable for the effectiveness of L-dopa. CONCLUSIONS: This is the first study to show a clear pharmacokinetic interaction between LDCD and MgO in humans. Further investigations to confirm the effects of MgO on the pharmacodynamics of L-dopa are required.
Asunto(s)
Antiparkinsonianos/sangre , Carbidopa/sangre , Levodopa/sangre , Óxido de Magnesio/farmacología , Modelos Biológicos , Administración Oral , Adulto , Animales , Antiparkinsonianos/administración & dosificación , Carbidopa/administración & dosificación , Simulación por Computador , Combinación de Medicamentos , Interacciones Farmacológicas , Estabilidad de Medicamentos , Femenino , Voluntarios Sanos , Humanos , Inyecciones Intravenosas , Levodopa/administración & dosificación , Óxido de Magnesio/administración & dosificación , Masculino , Ratas Wistar , Adulto JovenRESUMEN
Parkinson's disease caused by lack of dopamine in brain is a common neurodegenerative disorder. The traditional treatment is to replenish levodopa since it could pass through blood brain barrier and form dopamine. However, its accumulation can cause patients' movement disorders and uncontrollable emotion. Therefore, it is critical to control the levodopa dosage accuracy to improve the curative effect in clinical. In this study, a smartphone-based electrochemical detection system was developed for rapid monitoring of levodopa. The system involved a disposable sensor, a hand-held electrochemical detector, and a smartphone with designed application. Single-wall carbon nanotubes and gold nanoparticles modified screen-printed electrodes were used to convert and amplify the electrochemical current signals upon presence of levodopa molecules. The electrochemical detectors were used to generate electrochemical excitation signals and detect the resultant currents. Smartphone was connected to the detector, which was used to control the detector, calculate data, and plot graph in real-time. The smartphone-based differential pulse amperometry system was demonstrated to monitor levodopa at concentrations as low as 0.5⯵M in human serum. Furthermore, it has also been verified to be able to distinguish levodopa from other representative substances in the body. Therefore, its performance was more sensitive and rapid than electrochemical workstation. With these advantages, the system can be used in the field of point-of-care testing (POCT) to detect levodopa and provide the possibility to solve clinical demand for levodopa detection.
Asunto(s)
Antiparkinsonianos/sangre , Técnicas Biosensibles/instrumentación , Técnicas Electroquímicas/instrumentación , Oro/química , Levodopa/sangre , Nanopartículas del Metal/química , Nanotubos de Carbono/química , Monitoreo de Drogas/instrumentación , Electrodos , Diseño de Equipo , Humanos , Límite de Detección , Modelos Moleculares , Enfermedad de Parkinson/tratamiento farmacológico , Teléfono InteligenteRESUMEN
As of March 2018, rasagiline is approved for the treatment of Parkinson disease in 55 countries including Japan. The present study evaluated the pharmacokinetics (PK) and safety of rasagiline in healthy Japanese and Caucasian subjects following single and multiple administrations of three rasagiline doses. In this double-blind, placebo-controlled study, 64 healthy subjects (32 Japanese and 32 Caucasian) received either rasagiline (0.5, 1.0, or 2.0 mg) or placebo for 10 days with PK sampling for single-dose administration on day 1 and for multiple administration on day 10. Regardless of administration schedule, rasagiline plasma concentrations and dose-related increases in exposure parameters were similar between Japanese and Caucasians. Rasagiline accumulation (2-fold for 0.5 mg and 3-fold for 1.0 mg and 2.0 mg doses) following multiple administration was similar across the ethnic groups. Geometric mean ratios (GMR) comparing Japanese to Caucasians for AUC0-24 , Cmax and AUCinf following single administration were 1.38, 1.17 and 1.38 for 0.5 mg; 1.22, 1.20 and 1.22 at 1.0 mg; and 1.02, 1.00 and 1.02 at for 2.0 mg. GMR for AUCtau and Cmax,ss following multiple administration were 1.43 and 1.06 at 0.5 mg, 1.06 and 1.00 at 1.0 mg, and 1.09 and 1.07 at 2.0 mg. Safety measures were unremarkable and similar between Caucasian and Japanese subjects. Comparable systemic exposure and safety parameters were demonstrated for rasagiline administered to healthy Japanese and Caucasian subjects.
Asunto(s)
Antiparkinsonianos/administración & dosificación , Antiparkinsonianos/farmacocinética , Indanos/administración & dosificación , Indanos/farmacocinética , Adulto , Antiparkinsonianos/efectos adversos , Antiparkinsonianos/sangre , Pueblo Asiatico , Método Doble Ciego , Esquema de Medicación , Femenino , Humanos , Indanos/efectos adversos , Indanos/sangre , Masculino , Población Blanca , Adulto JovenRESUMEN
INTRODUCTION: To evaluate the effect of DA-9701, a novel prokinetic drug, on gastric motility evaluated by magnetic resonance imaging in patients with Parkinson's disease (PD). METHODS: Forty PD patients were randomly allocated to receive either domperidone or DA-9701. Their gastric functions were evaluated using magnetic resonance imaging before and after 4-week treatment period. Information on levodopa daily dose, disease duration, and Unified PD Rating Scale scores was collected. In 18 patients (domperidone: 9, DA-9701: 9), plasma levodopa concentrations were determined. Primary outcome was assessed by a one-sided 95% confidence interval to show non-inferiority of DA-9701 vs. domperidone with a pre-determined non-inferiority margin of -10%. RESULTS: Thirty-eight participants (19 men and 19 women; mean age, 67.1 years) completed the study protocol (domperidone: DA-9701â¯=â¯19:19). Gastric emptying rate at 120â¯min (2-hr GER) was comparable between the 2 groups; it was not correlated with levodopa daily dose or disease duration or Unified PD Rating Scale scores (all pâ¯>â¯0.05). DA-9701 was not inferior to domperidone in changes of 2-hr GERs before and after the treatment (absolute difference, 4.0 %; one-sided 95% confidence interval, - 3.7 to infinity). However, a significant increase in 2-hr GER was observed only in DA-9701 group (54.5% and 61.8%, before and after treatment, respectively, pâ¯<â¯0.05). Plasma levodopa concentration showed an insignificant but increasing trend in DA-9701 group. There were neither adverse reactions nor deteriorations of parkinsonian symptoms observed in the study participants. CONCLUSION: DA-9701 can be used for the patients with PD to enhance gastric motility without aggravating PD symptoms (ClinicalTrials.gov number: NCT03022201).
Asunto(s)
Antieméticos/farmacología , Antiparkinsonianos/sangre , Domperidona/farmacología , Vaciamiento Gástrico/efectos de los fármacos , Levodopa/sangre , Enfermedad de Parkinson/tratamiento farmacológico , Preparaciones de Plantas/farmacología , Estómago/efectos de los fármacos , Anciano , Antieméticos/administración & dosificación , Antiparkinsonianos/administración & dosificación , Domperidona/administración & dosificación , Método Doble Ciego , Femenino , Humanos , Levodopa/administración & dosificación , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Preparaciones de Plantas/administración & dosificación , Estómago/diagnóstico por imagen , Resultado del TratamientoRESUMEN
Levodopa-carbidopa intestinal gel (LCIG) is an effective treatment for Parkinson disease. Initiating therapy involves an initial naso-jejunal (NJ) titration phase. The NJ phase is prolonged with significant morbidity. The aim of this study is to assess the impact of proceeding without the NJ phase on resource utilisation and the outcomes of patients. Twenty-five patients were started on LCIG using the patients existing levodopa equivalent dose (LED). We recorded change in LED, length of hospital stay, readmission rates and use of outpatient services and clinical outcomes within 6 months. The median length of stay was 4.5 days. Patients had four outpatient clinic reviews and 2.5 community nurse contacts within 6 months. There was no significant change in daily LED on discharge (P = 0.56). There were significant improvements in all Unified Parkinson Disease Rating Scale subscores (P < 0.05), the Freezing of Gait scale (P < 0.01) and Parkinson Disease Quality Of Life 39 score (P < 0.01). Initiating LCIG without the NJ phase resulted in short admissions, a minimal outpatient burden and no significant requirement for dose titration while producing good clinical outcomes.
Asunto(s)
Antiparkinsonianos/administración & dosificación , Carbidopa/administración & dosificación , Yeyuno/efectos de los fármacos , Tiempo de Internación/tendencias , Levodopa/administración & dosificación , Enfermedad de Parkinson/diagnóstico , Enfermedad de Parkinson/tratamiento farmacológico , Administración Intranasal , Anciano , Antiparkinsonianos/sangre , Carbidopa/sangre , Combinación de Medicamentos , Femenino , Gastrostomía/métodos , Geles , Humanos , Bombas de Infusión Implantables , Yeyunostomía/métodos , Yeyuno/metabolismo , Levodopa/sangre , Masculino , Persona de Mediana Edad , Enfermedad de Parkinson/sangreRESUMEN
BACKGROUND: Droxidopa is an oral prodrug of norepinephrine approved for the treatment of symptomatic neurogenic orthostatic hypotension. This two-part, randomized, crossover study evaluated the 24-h pharmacokinetic profile of droxidopa in 24 healthy elderly subjects. METHODS: Noncompartmental analysis was used to calculate the area under the plasma concentration-time curve (AUC), maximum plasma concentration (Cmax), time of Cmax (tmax), and elimination half-life (t½e) of droxidopa and metabolites. Droxidopa was administered in the fed (high-fat/high-calorie meal) or fasted state either as a single 300-mg dose (three 100-mg capsules) or 3 times/day (TID) (three 100-mg capsules) at 4-h intervals. RESULTS: Administration of a single droxidopa dose in the fed versus fasted state decreased mean Cmax (2057 vs 3160 ng/mL) and mean AUC (10,927 vs 13,857 h × ng/mL) and increased median tmax twofold (4.00 vs 2.00 h). Differences between the fed and fasted state for mean t½e (2.58 vs 2.68 h) were not observed. Fed versus fasted geometric mean ratios for Cmax and AUC were 66% [90% confidence interval (CI) 60.7-71.7] and 80% (90% CI 72.6-88.1), respectively. With TID dosing, similar values for Cmax were observed after each dose (range 2789-3389 ng/mL) with no return to baseline between doses. Norepinephrine Cmax was 895 pg/mL following dose 1, with no further increases upon subsequent doses; norepinephrine levels remained above baseline for 12-16 h after dose 1. CONCLUSIONS: Absorption of a single dose of droxidopa is slowed after a high-fat/high-calorie meal; for consistent effect, administer droxidopa in the same manner (with or without food). Pharmacokinetic parameters of droxidopa are similar after single and TID dosing. ClinicalTrials.gov Identifier: NCT01149629.
Asunto(s)
Droxidopa/farmacocinética , Ayuno , Interacciones Alimento-Droga , Administración Oral , Anciano , Antiparkinsonianos/sangre , Antiparkinsonianos/farmacocinética , Disponibilidad Biológica , Estudios Cruzados , Droxidopa/sangre , Femenino , Voluntarios Sanos , Humanos , MasculinoRESUMEN
Levodopa is the most effective antiparkinsonian agent, but chronic treatment is associated with the development of motor complications in the majority of patients with PD. Recent scientific and clinical advances are improving this situation. Long-term, double-blind studies demonstrate that dose is an important risk factor for the development of both motor fluctuations and dyskinesia, and suggest that it is best to use low doses of l-dopa when possible. Inhaled l-dopa and sublingual apomorphine are now being developed as rescue therapies that permit rapid and predictable reversal of off periods. Finally, substantial evidence suggests that motor complications are related to the nonphysiological restoration of brain dopamine with intermittent oral doses of standard l-dopa. Double-blind studies demonstrate significant clinical benefits with continuous intraintestinal infusion of l-dopa. New approaches that provide continuous plasma l-dopa levels without the need for a surgical procedure are currently being investigated. Finally, the development of an oral long-acting form of l-dopa that provides continuous plasma l-dopa levels is actively being pursued. Collectively, these approaches offer the potential to considerably reduce and even prevent the disability associated with l-dopa-induced motor complications. © 2017 International Parkinson and Movement Disorder Society.
Asunto(s)
Antiparkinsonianos/efectos adversos , Discinesia Inducida por Medicamentos/etiología , Enfermedad de Parkinson/tratamiento farmacológico , Factores de Edad , Antiparkinsonianos/sangre , Humanos , Levodopa/efectos adversos , Levodopa/sangre , Resultado del TratamientoRESUMEN
Ropinirole is a very important treatment option for Parkinson's disease (PD), a major threat to the aging population. However, this drug undergoes extensive first-pass metabolism, resulting in a low oral bioavailability. Moreover, the necessity of frequent administration due to the short half-life of ropinirole may jeopardize patient compliance. Indeed, taking this drug in solid oral dosage forms (e.g. Tablet) can be a challenge because of the tremor, rigidity, limited mobility, and impaired drug absorption experienced by PD patients. In light of these, there is a pressing need to devise formulations for the delivery of ropinirole that allow simple and easy administration and fast drug action, as well as avoidance of first-pass metabolism and overcoming the challenge of impaired absorption due to gastrointestinal dysfunctions, etc. Herein, we seek to overcome all these challenges via sublingual or buccal delivery of orally-dissolving films. Accordingly, we aimed to fabricate and characterize orally-dissolving films of ropinirole and assess their in vivo pharmacokinetics after sublingual and buccal administration. The ropinirole oral film was non-toxic and exhibited fast disintegration and dissolution and was physically stable for at least 28â¯days. Upon buccal/sublingual administration of the oral films, ropinirole reached the systemic circulation within 15â¯min and bioavailability was significantly improved, which may be attributable to avoidance of first-pass metabolism via absorption through the oral cavity. In conclusion, our ropinirole oral film improved bioavailability after sublingual or buccal administration. This formulation potentially overcomes biopharmaceutical challenges and provide a convenient means of administration of ropinirole or other anti-PD drugs.
Asunto(s)
Antiparkinsonianos/farmacocinética , Preparaciones de Acción Retardada/química , Derivados de la Hipromelosa/química , Indoles/farmacocinética , Polietilenglicoles/química , Administración Bucal , Administración Sublingual , Animales , Antiparkinsonianos/sangre , Disponibilidad Biológica , Estabilidad de Medicamentos , Semivida , Humanos , Indoles/sangre , Boca/metabolismo , Enfermedad de Parkinson/tratamiento farmacológico , ConejosRESUMEN
OBJECTIVES: Blockade of N-methyl-D-aspartate receptors containing the NR2B subunit has been shown to be therapeutic in animal models of Parkinson disease (PD). However, findings with investigational NR2B receptor antagonists in PD patients have been mixed. The objective of this study was to evaluate the effects of the NR2B selective N-methyl-D-aspartate receptor antagonist MK-0657 on levodopa-induced dyskinesias and motor symptoms in PD patients. METHODS: A randomized, double-blind, single-dose, 2-period crossover study was conducted in 22 patients with PD and levodopa-induced peak-dose dyskinesias. Patients received oral MK-0657 (7 mg) or placebo, in randomized order, on each of 2 test days. On both days, levodopa was administered as a 2-hour intravenous infusion at greater than or equal to 1 mg/kg per hour with frequent assessments of dyskinesia, motor function, and pharmacokinetics. RESULTS: MK-0657 7 mg had no significant effect on dyskinesias (difference versus placebo in modified Abnormal Involuntary Movement Scale mean change from baseline area under the curve over 5 hours, -2.3; 95% confidence interval, -5.1 to 0.4) or motor function (difference versus placebo in Unified Parkinson's Disease Rating Scale Part III mean change from baseline area under the curve over 5 hours, 13.9; 95% confidence interval, -1.7 to 29.5). MK-0657 7 mg achieved the target mean maximum plasma concentration of 400 nM. CONCLUSIONS: These data suggest that a single dose of MK-0657 7 mg is not effective in improving levodopa-induced dyskinesias and motor symptoms in PD patients. CLINICAL TRIAL REGISTRATION: clinicaltrials.gov NCT00505843.